![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 31, 2026
This phase 2 clinical trial is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
December 19, 2025
Timely updates on research leaders, presentations at medical meetings and more
June 11, 2024
A Spring Group Meeting recap; a milestone for TMIST; a new myeloMATCH treatment trial
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
April 15, 2022
In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.